GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Does a Regenerative Medicine Plan Number Show?

A regenerative medicine plan number identifies a provision plan filed in Japan. Use it to find the associated documents and check the institution, procedure, risk class, and reviewing committee. The number itself does not establish the plan’s current status, product approval, treatment effectiveness, or suitability for you. Those checks require the current documents and, for personal suitability, a medical assessment. Plan

For scale, Japan had 6,743 treatment plans and 85 research plans on file as of 30 June 2026. Separately, PMDA reported 26 approved regenerative medical products as of 20 May 2026, excluding two withdrawn or expired approvals. These are different regulatory categories, not comparable measures of clinical success. 001590173.pdf000280868.pdf

What Does a Regenerative Medicine Plan Number Show?

This guide covers Japan’s regenerative medicine provision plans. It is general information, not personal medical advice or verification of a particular clinic.

What the Number Identifies

Under Japan’s Act on the Safety of Regenerative Medicine, procedures within the law’s scope require a provision plan and certified committee review, with requirements that depend on the risk class. The plan number is a reference for that filing, not a certificate that a treatment works. Filing is one part of a wider framework that also includes reporting and oversight obligations. Plan

Ask for the complete number and the institution’s official Japanese name. A brochure or screenshot can help you locate a record, but should not be your only evidence of its current status. The MHLW regenerative medicine portal provides routes to the relevant official systems, including e-Regenerative Medicine and jRCT. Index

The site’s registration-and-compliance overview explains the terminology used in the treatment process. Neither replaces the official documents for the number you were given.

What to Check in the Documents

Use the number to locate the public filing, then request supporting documents from the institution where necessary. Do not assume that every detail below appears in a public search result. Read the current plan, treatment explanation, consent materials, and relevant committee documents together. IndexPlan

Item What to compare Question to resolve
Institution and location The official Japanese name and treatment address against your quote and consent form Is this the institution and location that will provide your care?
Responsible clinician The named medical responsibility against the treating team’s explanation Who assesses you, performs the procedure, and handles complications?
Procedure and intended recipients The procedure, intended condition, and eligibility criteria against what you were offered Does the documented scope cover your proposed treatment?
Cells and administration Cell source, processing, dose or dosing method, route, and session schedule across the relevant documents Do the quote and consent materials describe the same intervention?
Risk class and committee The stated class, reviewing committee, and relevant review documents Do these relate to this plan rather than another procedure?
Dates and amendments The latest available plan and any changes against the documents supplied to you Is the clinic relying on current documents, and is provision continuing?
Processing and follow-up Processing arrangements, follow-up, and complication management in the plan and patient materials Who is responsible at each stage? The cell-processing overview explains related terms.

Risk Class Is Not an Effectiveness Score

Classes I, II, and III are risk-based regulatory categories with different procedural requirements. They are not treatment-success ratings or guarantees of individual safety. Read the stated class in the documents rather than trying to infer it from a number’s letters or digits. Plan

A Number Does Not Date the Documents

Check amendments and current provision status separately. Do not assume that a changed plan must have a different number, or that an unchanged number means the documents have not changed. Ask the institution to identify the latest applicable plan and the committee review relevant to the proposed procedure. MHLW’s framework also provides for discontinuation or completion of provision; possession of a number alone does not establish ongoing availability. Plan

What Filing Does Not Prove

Record What it establishes What it does not establish alone
Filed provision plan A plan has been submitted under the safety framework Clinical benefit, compliance on the day of treatment, or personal suitability
Regenerative medical product approval The named product has an approval with specified uses and conditions Benefit for every condition or patient, or unrestricted use
Study registration The study has a registry entry describing its planned conduct That recruitment began, the study finished, or results showed benefit

The relevant records come from different systems. Check the provision-plan requirements, product approval information, or study entry according to the claim being made. Plan0003En top

Product Approval Is a Separate Check

PMDA reviews regenerative medical products for marketing approval; a provision-plan filing is not that approval. If a clinic says a product is approved, request its name, approved indication, and applicable conditions. Some Japanese regenerative medical product approvals are conditional and time-limited, with subsequent efficacy evaluation required. An approval claim therefore needs its exact terms, not just the word “approved.” 0003000280868.pdf

Effectiveness Needs Clinical Evidence

Neither a provision-plan number nor a jRCT entry establishes a successful outcome. For a treatment claim, ask for published human evidence relevant to your condition, cell type, processing method, and administration route. Look for the study population, comparison group, number of participants, measured outcomes, follow-up duration, and adverse events. A registry describes a study; its existence is not a substitute for results. En top

Personal Suitability Needs Assessment

Even matching documents cannot determine whether a procedure is appropriate for you. Ask a qualified clinician to assess your diagnosis, medical history, medicines, alternatives, and the proposed intervention’s risks and uncertainties. The site’s safety overview is background reading, not an individual assessment.

How to Check a Plan Number

  1. Copy the identifier exactly. Keep the complete number, official institution name, proposed procedure, and date you received the information.
  2. Start from MHLW. Follow its official links to the published provision-plan information. For research, also request the study identifier and check the relevant jRCT entry. Save the record URL and your lookup date. IndexIndexEn top
  3. Compare the documents. Match the institution, procedure, cells, route, dates, and applicable review documents with the quote and consent materials. Ask the institution to explain gaps in writing.
  4. Check claims separately. Filing status, product approval, research participation, clinical evidence, and personal suitability each require their own check. Do not treat one identifier as the answer to all five.

A Document-Matching Scenario

Suppose a quote describes an intravenous infusion, but the supplied treatment explanation describes an injection into a joint. This is a hypothetical document-checking example, not a patient case. A matching plan number does not resolve the route discrepancy. Ask which route is proposed, where it appears in the current plan, and whether the consent form and quoted price cover that same procedure.

You can make the request specific: “Please send the current plan and relevant committee documents for this number, identify the section covering the proposed administration route, and explain any difference from my quote.” Keep the original Japanese text alongside any translation so the institution can identify the exact wording in question.

If the Record Will Not Open

A failed search or inaccessible page does not establish that a plan is valid or invalid. Try the route from MHLW’s portal, ask the institution for the current documents, and request an official contact for unresolved questions. Do not replace a missing record with an agent’s reassurance. Guidance on choosing a hospital in Japan can help structure your questions, but cannot authenticate a specific filing.

When to Pause Before Paying

  • The institution will not provide its complete identifier or explain how to verify the current plan.
  • The supplied record names another institution or a procedure different from the one offered.
  • The review documents concern a different plan, or amendments cannot be explained.
  • The quote and consent materials disagree about the cells, route, or sessions.
  • An approval claim cannot be tied to a named product, indication, and approval conditions.

Resolve these discrepancies before arranging medical travel or making a non-refundable payment. A discrepancy is a reason to investigate, not proof by itself that the provider has broken the law.

Compare treatment quotes only after checking the procedure, cell processing, route, sessions, follow-up, and complication arrangements. A lower price may cover a different service.

Japan’s Published Numbers in Context

Category Published count Snapshot date
Treatment provision plans 6,743: Class I 8, Class II 2,463, Class III 4,272 30 June 2026
Research provision plans 85: Class I 11, Class II 41, Class III 33 30 June 2026
Certified committees 167: 80 specially certified committees and 87 committees reviewing Class III plans only 30 June 2026
Approved regenerative medical products, excluding withdrawn or expired approvals 26; PMDA’s cumulative approval chart includes two additional withdrawn or expired approvals 20 May 2026

The plan and committee figures are from MHLW; the product figure is from PMDA. These dated snapshots count different things: plans, committees, and product approvals. None is a treatment-success rate, and none establishes the current status of a particular offer. 001590173.pdf000280868.pdf

Have questions about a plan number?

Use the contact form to ask what document-checking support is available. Include the plan number and official institution name, but do not send sensitive medical records in an initial enquiry. Any assistance does not replace official confirmation or medical advice.

Ask About a Plan Number

The Bottom Line

A plan number helps you identify a filed plan, not a proven treatment. Use the associated current documents to check the institution and proposed procedure, then assess approval claims and clinical evidence separately. Japan’s 6,743 treatment plans as of 30 June 2026 and 26 approved products excluding withdrawn or expired approvals as of 20 May 2026 belong to different regulatory categories. Neither count answers whether a particular intervention is right for you. 001590173.pdf000280868.pdf

References

  1. MHLW. Provision-plan procedures under the Act on the Safety of Regenerative Medicine. Japan. Accessed 3 November 2026. Provision-plan requirements.
  2. MHLW. Status of enforcement of the Act on the Safety of Regenerative Medicine, as of 30 June 2026. Japan. Accessed 3 November 2026. Plan and committee statistics.
  3. PMDA. Japan’s Regulatory Framework and Recent Updates on Regenerative Medical Products, 20 May 2026. Japan; product counts exclude withdrawn or expired approvals unless stated otherwise. Accessed 3 November 2026. Regulatory framework and statistics.
  4. MHLW. Regenerative medicine portal. Japan. Accessed 3 November 2026. Official portal.
  5. MHLW. e-Regenerative Medicine published-plan search. Japan; public information as available. Published-plan search.
  6. PMDA. Regenerative medical product review guidance, including conditional and time-limited approval guidance. Japan. Accessed 3 November 2026. Review guidance; Approved product information.
  7. Japan Registry of Clinical Trials. Japan; registry entries describe studies, not proof of benefit. Accessed 3 November 2026. jRCT.